Pfizer Putting On The Pressure, But AstraZeneca Still Hard To Get
This article was originally published in The Pink Sheet Daily
Pfizer execs speak of complementary drug portfolios and pipelines. Market watchers, however, believe the merger interest is driven more by financial rationale: a lower corporate tax rate, a way to use ex-U.S. cash and the likelihood of significant synergies. U.K. law sets May 26 deadline for a new bid.